- NCIt
- C116915
Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06482515 | Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue | recruiting | Phase 2 | 96 | University of Maryland, BaltimoreOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial(PRAGMATIC) | recruiting | Phase 2 | 104 | The University of QueenslandOTHER | 2 | Apr 16, 2026 | clinicaltrials |
| NCT05873205 | Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07148180 |
Data updated 22 days agoSource updated Jun 5, 2026source: clinicaltrials
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax |
| recruiting |
| Phase 1 / Phase 2 |
| 31 |
| Jacqueline Garcia, MDOTHER |
| 1 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |